© 2004 BMJ Publishing Group Ltd & British Thoracic Society
EDITORIAL
TB and anti-TNF-
treatment
Tuberculosis and anti-TNF-
treatment
Correspondence to:
Correspondence to:
Professor L P Ormerod
Chest Clinic, Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, UK; Peter.Ormerod@mail.bhrv.nwest.nhs.uk
New evidence-based guidance on anti-TNF-
treatment is being developed by the Joint Tuberculosis Committee of the BTS in conjunction with the British Societies of Rheumatology and Gastroenterology
Keywords: tuberculosis; anti-tumour necrosis factor-; adverse drug reaction
| The first 150 words of the full text of this article appear below. |
Anti-tumour necrosis factor (TNF) treatment for rheumatoid arthritis and Crohn’s disease has been introduced over the last few years. Infliximab (Remicade; Schering-Plough), a humanised monoclonal antibody, is licensed for the treatment of both rheumatoid arthritis1 and Crohn’s disease,2 while etanercept (Enbrel; Wyeth Laboratories), a fusion protein binding free TNF- using the soluble portion of the TNFR-2 receptor,3 and adalimumab (Humira; Abbott Laboratories), a fully humanised monoclonal antibody,4 are licensed for treating rheumatoid arthritis. Post-marketing surveillance in the USA5 has identified cases of tuberculosis (TB) associated with infliximab use and a smaller number with etanercept. TB cases have also been reported in association with adalimumab (Humira prescribing information, Abbott Laboratories, 2002). The cases associated with infliximab occurred within three cycles of treatment, with a median of 12 weeks from commencing treatment,5 and most were in extrapulmonary sites.6 Calculations have suggested that TB rates in patients in the
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Demissie, A., Leyten, E. M. S., Abebe, M., Wassie, L., Aseffa, A., Abate, G., Fletcher, H., Owiafe, P., Hill, P. C., Brookes, R., Rook, G., Zumla, A., Arend, S. M., Klein, M., Ottenhoff, T. H. M., Andersen, P., Doherty, T. M., the VACSEL Study Group,
(2006). Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis. CVI
13: 179-186
[Abstract] [Full Text] -
Keane, J.
(2005). TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford)
44: 714-720
[Abstract] [Full Text]
eLetters:
Read all eLetters
- Tuberculosis and anti-TNF- treatment
- Prasanta Raghab Mohapatra, et al.
- Thorax Online, 19 Nov 2004 [Full text]
- Tuberculosis screening and anti-TNF-alpha therapy
- Giuseppe Provenzano, et al.
- Thorax Online, 14 Feb 2005 [Full text]
- Full Text
- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Drugs: infectious diseases
-
Unwanted effects / adverse reactions
-
Vaccination / immunisation
-
Screening (epidemiology)
- Screening (public health)
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
